Navigation Links
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Date:1/27/2009

PALO ALTO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- In light of an announcement made recently by Astellas Pharma Inc., CV Therapeutics, Inc. (Nasdaq: CVTX) confirmed that it had received a letter dated November 13, 2008 from Astellas setting forth an unsolicited proposal by Astellas to acquire CV Therapeutics at a price of $16.00 per share, subject to due diligence, Astellas board approval and other conditions.

After careful deliberation, with the assistance of its financial and legal advisors, the CV Therapeutics board of directors had, on November 21, 2008, concluded that the Astellas proposal was not in the best interests of CV Therapeutics and its stockholders. Dr. Louis Lange, chairman and chief executive officer of CV Therapeutics, sent a letter dated November 21, 2008 to that effect to Astellas on behalf of the board of directors of CV Therapeutics.

Because Astellas, by its recent announcement, has sought to revive its previously rejected proposal, the CV Therapeutics board of directors will again review developments in the context of the company's strategic plans and the long-term interests of its stockholders, to pursue the best course of action to maximize long-term value for stockholders. As part of its ongoing review of the current market environment and the recent developments relating to CV Therapeutics, the board of CV Therapeutics concluded that it was in the best interests of CV Therapeutics and its stockholders to extend the expiration date of its shareholder rights plan from February 1, 2009 to February 1, 2010. CV Therapeutics will keep its stockholders advised.

Barclays Capital is serving as financial advisor, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3
... Madison, Wis. -- Two years ago, I signed a bud...e state,s history. And on Monday, I signed a budg... our state asked us to do three things with this b...priority, and freeze property taxes. I,m pleased ...ed up to our commitment to Wisconsin families. , ,...
...The Wisconsin Alumni Research Foundation has lic...Chemicon to commercialize research products using...ny Serologicals announced Tuesday. , ,Chemicon w...of stem cell technologies, which were developed an...dison . , ,Jeff Linton, president of Chemicon, sa...
... - Firstlogic, Inc ., a provider of enterprise i...that Crate and Barrel housewares retailer has de...anage the data quality in its new customer managem...stlogic,s software suite to achieve data quality i...nels where customer and product data flows.The sys...
Other Biology Technology:A budget that moves Wisconsin forward 2A budget that moves Wisconsin forward 3A budget that moves Wisconsin forward 4WARF signs stem cell agreement with California firm 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 1Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 2In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 1In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 2Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 1Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 2Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 3
...researchers have developed a computer modeling app... antibodies, molecules key to the immune system. T...body that will improve its effectiveness. , The ...rsion of cetuximab, a drug commonly used to treat ...0 times greater affinity than the original molecul...
... bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a lead... today announced that it has acquired a patent tha...ecure portable locks. The company believes that t.... For many years, consumers have been using portab...to secure personal belongings in lockers,and stora...
..., Sept. 10 ,Communication Intelligence Corporation...lier of electronic signature solutions for busines... the recognized leader in biometric,signature veri...el Betts to,the CIC Board of Directors. Mr. Betts...and,financial services industries and holds the FL...
Other Biology News:MIT model could improve some drugs' effectiveness 2MIT model could improve some drugs' effectiveness 3bioMETRX, Inc. Acquires Patent for Biometric Padlock 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
(Miller's LB Broth Base) Luria Broth Base powder from Invitrogen
Rat TNF-alpha ELISA Kit, OptEIA from BD Biosciences Pharmingen
LB Broth Base powder (Lennox L Broth Base) from Invitrogen
Biology Products: